Ototoxicity
Information
- Disease name
- Ototoxicity
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT00683319 | Active, not recruiting | Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy | April 2008 | ||
| NCT00477607 | Completed | Phase 2/Phase 3 | Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin | October 2007 | June 2011 |
| NCT00458887 | Completed | Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin | May 2007 | February 28, 2017 | |
| NCT00652132 | Completed | Phase 3 | Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer | December 15, 2007 | February 28, 2018 |
| NCT00716976 | Completed | Phase 3 | Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy | June 23, 2008 | June 30, 2021 |
| NCT01139281 | Completed | Phase 2 | The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans | June 2007 | June 2008 |
| NCT04262336 | Completed | Phase 1 | Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment | February 21, 2020 | May 23, 2023 |
| NCT01263262 | Completed | A Comparison of Infection Rates Between Two Surgical Sites | January 2011 | August 2013 | |
| NCT01848457 | Completed | Phase 2 | Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy | April 2013 | October 1, 2016 |
| NCT02819856 | Enrolling by invitation | Phase 2 | SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity | July 21, 2017 | April 2023 |
| NCT05641441 | Recruiting | Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma | January 24, 2023 | November 15, 2030 | |
| NCT04226456 | Terminated | Phase 4 | Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity | July 10, 2021 | September 3, 2023 |
| NCT01451853 | Unknown status | Phase 2 | SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss | January 15, 2018 | September 23, 2019 |
| NCT01285674 | Unknown status | N/A | Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin. | January 2011 | January 2012 |
| NCT03480971 | Unknown status | Phase 2 | Treatment of Radiation and Cisplatin Induced Toxicities With Tempol | May 13, 2019 | April 2023 |
| NCT00578760 | Unknown status | N/A | Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity? | February 2008 | February 2010 |
| NCT01624324 | Unknown status | Aminoglycoside Plasma Level Measurement in Neonates With Infection | November 2010 | ||
| NCT01216800 | Unknown status | Phase 3 | Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors | August 2008 | |
| NCT02382068 | Withdrawn | N/A | Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin | August 2014 | July 2017 |